Involvement of the opioid and cannabinoid systems in pain control: New insights from knockout studies

European Journal of Pharmacology

Volumn 716, Issue 1-3, 2013, Pages 142-157

  Nadal, Xavier ^a   La Porta, Carmen ^a   Bura, S Andreea ^a   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Cannabinoid receptor; Fatty acid amide hydrolase; Monoacylglycerol lipase; Neprilysin; Opioid receptor; Tolerance

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACYLGLYCEROL LIPASE; ANALGESIC AGENT; ANANDAMIDE; AZ 11713908; BETA ENDORPHIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CP 55 940; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DELTA OPIATE RECEPTOR; DEXANABINOL; ENDOCANNABINOID; ENDORPHIN; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NEPRYLISINE; PF 3845; PRODYNORPHIN; PROENKEPHALIN; PROTEINASE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANTINOCICEPTION; DISEASE CONTROL; EXPERIMENTAL MODEL; GENE INACTIVATION; INFLAMMATORY PAIN; KNOCKOUT MOUSE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; VISCERAL PAIN;

CANNABINOID RECEPTOR; FATTY-ACID AMIDE HYDROLASE; MONOACYLGLYCEROL LIPASE; NEPRILYSIN; OPIOID RECEPTOR; TOLERANCE;

ANALGESICS, OPIOID; ANIMALS; CANNABINOIDS; GENE KNOCKOUT TECHNIQUES; PAIN;

EID: 84892541489     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.01.077     Document Type: Review

References (156)

1. Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C.E., Brenner, G.J., Rubino, T., Michalski, C.W., Marsicano, G., Monory, K., Mackie, K., Marian, C., Batkai, S., Parolaro, D., Fischer, M.J., Reeh, P., Kunos, G., Kress, M., Lutz, B., Woolf, C.J., Kuner, R., 2007. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci., 10; 870-879.
2. Ahn, K., Johnson, D.S., Mileni, M., Beidler, D., Long, J.Z., McKinney, M.K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S.E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van Becelaere, K., Stevens, R.C., Cravatt, B.F., 2009. Discovery and characterization of a highly selective FAAH inhibitor that reduces in.ammatory pain. Chem. Biol. 16, 411-420.
3. Akil, H., Meng, F., Devine, D.P., Watson, S.j., 1997. Molecular and neuroanatomical properties of the endogenous opioid systems: implications for the treatment of opiate addiction. Semin. Neurosci. 9, 70-93.
4. Anton, B., Fein, J., To, T., Li, X., Silberstein, L., Evans, C.J., 1996. Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J. Comp. Neurol. 368, 229-251.
5. Baker, D., Pryce, G., Davies, W.L., Hiley, C.R., 2006. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27, 1-4.
6. Bian, D., Ossipov, M.H., Ibrahim, M., Raffa, R.B., Tallarida, R.J., Malan Jr., T.P., Lai, J., Porreca, F., 1999. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. Brain Res. 831, 55-63.
7. Bilkei-Gorzo, A., Racz, I., Michel, K., Zimmer, A.M., Klingmüller, D., Zimmer, A., Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds. Psychopharmacology 176, 343-352.
8. Booker, L., Kinsey, S.G., Abdullah, R.A., Blankman, J.L., Long, J.Z., Ezzili, C., Boger, D.L., Cravatt, B.F., Lichtman, A.H., 2012. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br. J. Pharmacol. 165, 2485-2496.
9. Bridges, D., Rice, A.S., Egertova, M., Elphick, M.R., Winter, J., Michael, G.J., 2003. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119, 803-812.
10. Brusberg, M., Arvidsson, S., Kang, D., Larsson, H., Lindström, E., Martinez, V., 2009. CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents. J. Neurosci. 29, 1554-1564.
11. Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D., 1998. Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281.
12. Castañé, A., Célérier, E., Martín, M., Ledent, C., Parmentier, M., Maldonado, R., Valverde, O., 2006. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 50, 111-122.
13. Castañe, A., Robledo, P., Matifas, A., Kieffer, B.L., Maldonado, R., 2003. Cannabinoid withdrawal syndrome is reduced in double A and y opioid receptor knockout mice. Eur. J. Neurosci. 17, 155-159.
14. Chang, L., Luo, L., Palmer, J.A., Sutton, S., Wilson, S.J., Barbier, A.J., Breitenbucher, J.G., Chaplan, S.R.,Webb, M., 2006. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148, 102-113.
15. Chen, T.C., Cheng, Y.Y., Sun, W.Z., Shyu, B.C., 2008. Differential regulation of morphine antinociceptive effects by endogenous enkephalinergic system in the forebrain of mice. Mol. Pain 4, 41.
16. Clement, A.C., Hawkins, E.G., Lichtman, A.H., Cravatt, B.F., 2003. Increased seizure susceptibility and pro-convulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916-3923.
17. Contet, C., Gavériaux-Ruff, C., Matifas, A., Caradec, C., Champy, M.F., Kieffer, B.L., 2006. Dissociation of analgesic and hormonal responses to forced swim stress using opioid receptor knockout mice. Neuropsychopharmacology 31, 1733-1744.
18. Conti, S., Costa, B., Colleoni, M., Parolaro, D., Giagnoni, G., 2002. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 135, 181-187.
19. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., Lichtman, A.H., 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98, 9371-9376.
20. Cravatt, B.F., Lichtman, A.H., 2004. The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol. 61, 149-160.
21. Cravatt, B.F., Saghatelian, A., Hawkins, E.G., Clement, A.B., Bracey, M.H., Lichtman, A.H., Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. USA 101, 10821-10826.
22. Davidson, E., Coppey, L., Lu, B., Arballo, V., Calcutt, N.A., Gerard, C., Yorek, M., 2009. The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp. Diabetes Res. 2009, 431980.
23. Devane, W.A., Dysarz III, F.A., Johnson, M.R., Melvin, L.S., Howlett, A.C., 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613.
24. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R., 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
25. Devi, L.A., 2001. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. Sci. 22, 532-537.
26. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C., Piomelli, D., Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
27. Di Marzo, V., Breivogel, C.S., Tao, Q., Bridgen, D.T., Razdan, R.K., Zimmer, A.M., Zimmer, A., Martin, B.R., 2000. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434-2444.
28. Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Kathuria, S., Piomelli, D., 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99, 10819-10824.
29. Dogrul, A., Gardell, L.R., Ma, S., Ossipov, M.H., Porreca, F., Lai, J., 2002. "Knock-down" of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. Pain 100, 203-209.
30. Drew, L.J., Harris, J., Millns, P.J., Kendall, D.A., Chapman, V., 2000. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur. J. Neurosci. 12, 2079-2086.
31. Fields, H., 2004. State-dependent opioid control of pain. Nat. Rev. Neurosci. 5, 565-575.
32. Fields, H.L., Heinricher, M.M., Mason, P., 1991. Neurotransmitters in nociceptive modulatory circuits. Annu. Rev. Neurosci. 14, 219-245.
33. Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H.W., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., Valverde, O., Maldonado, R., Kieffer, B.L., 2000. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25, 195-200.
34. Fioravanti, B., De Felice, M., Stucky, C.L., Medler, K.A., Luo, M.C., Gardell, L.R., Ibrahim, M., Malan Jr., T.P., Yamamura, H.I., Ossipov, M.H., King, T., Lai, J., Porreca, F., Vanderah, T.W., 2008. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J. Neurosci. 28, 11593-11602.
35. Fischer, H.S., Zernig, G., Hauser, K.F., Gerard, C., Hersh, L.B., Saria, A., 2002. Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide. J. Mol. Neurosci. 18, 129-134.
36. Flake, N.M., Zweifel, L.S., 2012. Behavioral effects of pulp exposure in mice lacking cannabinoid receptor 2. J. Endod. 38, 86-90.
37. Fuchs, P.N., Roza, C., Sora, I., Uhl, G., Raja, S.N., 1999. Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice. Brain Res. 821, 480-486.
38. Gardell, L.R., Ossipov, M.H., Vanderah, T.W., Lai, J., Porreca, F., 2002. Dynorphin-independent spinal cannabinoid antinociception. Pain 100, 243-248.
39. Gavériaux-Ruff, C., Karchewski, L.A., Hever, X., Matifas, A., Kieffer, B.L., 2008. Inflammatory pain is enhanced in delta opioid receptor-knockout mice. Eur. J. Neurosci. 27, 2558-2567.
40. Gavériaux-Ruff, C., Nozaki, C., Nadal, X., Hever, X.C., Weibel, R., Matifas, A., Reiss, D., Filliol, D., Nassar, M.A., Wood, J.N., Maldonado, R., Kieffer, B.L., 2011. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 152, 1238-1248.
41. Gendron, L., Pintar, J.E., Chavkin, C., 2007. Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. Neuroscience 150, 807-817.
42. Ghozland, S., Mathews, H.W.D., Simonin, F., Filliol, D., Kieffer, B.L., Maldonado, R., Motivational effects of cannabinoids are mediated by A- and n-opioid receptors. J. Neurosci. 22, 1146-1154.
43. Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, P.A., Brusco, A., Uhl, G.R., Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 10-23.
44. Gray, A.C., Coupar, I.M., White, P.J., 2006. Comparison of opioid receptor distributions in the rat central nervous system. Life Sci. 79, 674-685.
45. Guo, X.H., Fairbanks, C.A., Stone, L.S., Loh, H.H., 2003. DPDPE-UK14,304 synergy is retained in mu opioid receptor knockout mice. Pain 104, 209-217.
46. Guyton, Arthur C., 1991. Textbook of Medical Physiology, 8th ed. W.B. Saunders, Philadelphia.
47. Haller, V.L., Stevens, D.L., Welch, S.P., 2008. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur. J. Pharmacol. 600, 50-58.
48. Hohmann, A.G., 2002. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids. 121, 173-190.
49. Hohmann, A.G., Herkenham, M., 1999. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90, 923-931.
50. Hosohata, Y., Vanderah, T.W., Burkey, T.H., Ossipov, M.H., Kovelowski, C.J., Sora, I., Uhl, G.R., Zhang, X., Rice, K.C., Roeske, W.R., Hruby, V.J., Yamamura, H.I., Lai, J., Porreca, F., 2000. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice. Eur. J. Pharmacol. 388, 241-248.
51. Hough, L.B., Nalwalk, J.W., Chen, Y., Schuller, A., Zhu, Y., Zhang, J., Menge, W.M., Leurs, R., Timmerman, H., Pintar, J.E., 2000. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res. 880, 102-108.
52. Ibrahim, M.M., Deng, H., Zvonok, A., Cockayne, D.A., Kwan, J., Mata, H.P., Vanderah, T.W., Lai, J., Porreca, F., Makriyannis, A., Malan, T.P., 2003. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl Acad. Sci. USA 100, 10529-10533.
53. Ibrahim, M.M., Porreca, F., Lai, J., Albrecht, P.J., Rice, F.L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T.W., Mata, H.P., Malan Jr., T.P., 2005. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. USA 102, 3093-3098.
54. Ibrahim, M.M., Rude, M.L., Stagg, N.J., Mata, H.P., Lai, J., Vanderah, T.W., Porreca, F., Buckley, N.E., Makriyannis, A., Malan Jr., T.P., 2006. CB2 cannabinoid receptor mediation of antinociception. Pain 122, 36-42.
55. Ide, S., Minami, M., Ishihara, K., Uhl, G.R., Satoh, M., Sora, I., Ikeda, K., 2008. Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in mu-opioid receptor knockout mice. Neuropharmacology 54, 1182-1188.
56. Ide, S., Minami,M., Uhl, G.R., Satoh,M., Sora, I., Ikeda, K., 2011. (-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice. Mol. Pain 7, 23.
57. Jayamanne, A., Greenwood, R., Mitchell, V.A., Aslan, S., Piomelli, D., Vaughan, C.W., Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147, 281-288.
58. Jhaveri, M.D., Sagar, D.R., Elmes, S.J., Kendall, D.A., Chapman, V., 2007. Cannabinoid CB(2) receptor-mediated anti-nociception in models of acute and chronic pain. Mol. Neurobiol. 36, 26-35.
59. Kieffer, B.L., Evans, C.J., 2009. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 56 (Suppl. 1), 205-212. (Epub 2008 August 5, 205-212).
60. Kieffer, B.L., Gavériaux-Ruff, C., 2002. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66, 285-306.
61. Kinsey, S.G., Long, J.Z., Cravatt, B.F., Lichtman, A.H., 2010. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J. Pain 11, 1420-1428.
62. Kinsey, S.G., Long, J.Z., O'Neal, S.T., Abdullah, R.A., Poklis, J.L., Boger, D.L., Cravatt, B.F., Lichtman, A.H., 2009. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther. 330, 902-910.
63. Kinsey, S.G., Naidu, P.S., Cravatt, B.F., Dudley, D.T., Lichtman, A.H., 2011. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol. Biochem. Behav. 99, 718-725.
64. Kitanaka, N., Sora, I., Kinsey, S., Zeng, Z., Uhl, G.R., 1998. No heroin or morphine 6beta-glucuronide analgesia in mu-opioid receptor knockout mice. Eur. J. Pharmacol. 355, R1-R3.
65. Kögel, B., De Vry, J., Tzschentke, T.M., Christoph, T., 2011. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice. Neurosci. Lett. 491, 104-107.
66. König, M., Zimmer, A.M., Steiner, H., Holmes, P.V., Crawley, J.N., Brownstein, M.J., Zimmer, A., 1996. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535-538.
67. Krämer, H.H., He, L., Lu, B., Birklein, F., Sommer, C., 2009. Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol. Dis. 35, 177-183.
68. La Porta, C., Bura, S.A., Aracil-Fernández, A., Manzanares, J., Maldonado, R., 2013. Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. Pain 154, 160-174.
69. LaBuda, C.J., Sora, I., Uhl, G.R., Fuchs, P.N., 2000. Stress-induced analgesia in muopioid receptor knockout mice reveals normal function of the delta-opioid receptor system. Brain Res. 869, 1-5.
70. Lauckner, J.E., Jensen, J.B., Chen, H.Y., Lu, H.C., Hille, B., Mackie, K., 2008. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci 105, 2699-2704.
71. Laughlin, T.M., Larson, A.A., Wilcox, G.L., 2001. Mechanisms of induction of persistent nociception by dynorphin. J. Pharmacol. Exp. Ther. 299, 6-11.
72. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., Bohme, G.A., Imperato, A., Pedrazzini, T., Roques, B.P., Vassart, G., Fratta, W., Parmentier, M., Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404.
73. Leichsenring, A., Andriske, M., Backer, I., Stichel, C.C., Lubbert, H., 2009. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn-Schmiedeberg's Arch. Pharmacol. 379, 627-636.
74. Lichtman, A.H., Shelton, C.C., Advani, T., Cravatt, B.F., 2004. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109, 319-327.
75. Liu, X.Y., Liu, Z.C., Sun, Y.G., Ross, M., Kim, S., Tsai, F.F., Li, Q.F., Jeffry, J., Kim, J.Y., Loh, H.H., Chen, Z.F., 2011. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147, 447-458.
76. Loh, H.H., Liu, H.C., Cavalli, A., Yang, W., Chen, Y.F., Wei, L.N., 1998. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res. Mol. Brain Res. 54, 321-326.
77. Lu, B., Gerard, N.P., Kolakowski Jr., L.F., Bozza, M., Zurakowski, D., Finco, O., Carroll, M.C., Gerard, C., 1995. Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181, 2271-2275.
78. Luongo, L., Palazzo, E., Tambaro, S., Giordano, C., Gatta, L., Scafuro, M.A., Rossi, F.S., Lazzari, P., Pani, L., de Novellis, V., Malcangio, M., Maione, S., 2010. 1-(2′,4′-dichlorophenyl)-6-methyl-N- cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol. Dis. 37, 177-185.
79. Maldonado, R., Valverde, O., 2003. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur. Neuropsychopharmacol. 13, 401-410.
80. Manning, B.H., Martin, W.J., Meng, I.D., 2003. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience 120, 1157-1170.
81. Mansour, A., Fox, C.A., Burke, S., Akil, H., Watson, S.J., 1995. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J. Chem. Neuroanat. 8, 283-305.
82. Martin, M., Matifas, A., Maldonado, R., Kieffer, B.L., 2003. Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. Eur. J. Neurosci. 17, 701-708.
83. Martin, W.J., Coffin, P.O., Attias, E., Balinsky, M., Tsou, K., Walker, J.M., 1999. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 20 (822), 237-242.
84. Martin, W.J., Tsou, K., Walker, J.M., 1998. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 242, 33-36.
85. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B.F., Ferri, G. L., Sibaev, A., Storr, M., Lutz, B., 2004. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209.
86. Matthes, H.W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B.P., Kieffer, B.L., 1996. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819-823.
87. Matthes, H.W., Smadja, C., Valverde, O., Vonesch, J.L., Foutz, A.S., Boudinot, E., Denavit-Saubié, M., Severini, C., Negri, L., Roques, B.P., Maldonado, R., Kieffer, B. L., 1998. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J. Neurosci. 18, 7285-7295.
88. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
89. Meng, I.D., Manning, B.H., Martin, W.J., Fields, H.L., 1998. An analgesia circuit activated by cannabinoids. Nature 395, 381-383.
90. Merskey, H., Bogduk, N., 1994. Classification of Chronic Pain. IASP Press, Seattle.
91. Miller, L.L., Picker, M.J., Schmidt, K.T., Dykstra, L.A., 2011. Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. Psychopharmacology 215, 455-465.
92. Millns, P.J., Chapman, V., Kendall, D.A., 2001. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br. J. Pharmacol. 132, 969-971.
93. Mizoguchi, H., Narita, M., Oji, D.E., Suganuma, C., Nagase, H., Sora, I., Uhl, G.R., Cheng, E.Y., Tseng, L.F., 1999. The mu-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in mu-opioid receptor knockout mice. Neuroscience 94, 203-207.
94. Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G.,Wotjak, C.T., Lutz, B., Marsicano, G., 2007. Genetic dissection of behavioral and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 5, e269.
95. Munro, S., Thomas, K.L., bu-Shaar, M., 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
96. Nadal, X., Baños, J.E., Kieffer, B.L., Maldonado, R., 2006. Neuropathic pain is enhanced in delta-opioid receptor knockout mice. Eur. J. Neurosci. 23, 830-834.
97. Naidu, P.S., Booker, L., Cravatt, B.F., Lichtman, A.H., 2009. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J. Pharmacol. Exp. Ther. 329, 48-56.
98. Naidu, P.S., Kinsey, S.G., Guo, T.L., Cravatt, B.F., Lichtman, A.H., 2010. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J. Pharmacol. Exp. Ther. 334, 182-190.
99. Narita, M., Imai, S., Nakamura, A., Ozeki, A., Asato, M., Rahmadi, M., Sudo, Y., Hojo, M., Uezono, Y., Devi, L.A., Kuzumaki, N., Suzuki, T., 2011. Possible involvement of prolonging spinal μ-opioid receptor desensitization in the development of anti-hyperalgesic tolerance to μ-opioids under a neuropathic pain-like state. Addict. Biol., http://dx.doi.org/10.1111/j.1369- 1600.2011.00354.x. [Epub ahead of print].
100. Nozaki, C., Le Bourdonnec, B., Reiss, D., Windh, R.T., Little, P.J., Dolle, R.E., Kieffer, B. L., Gavériaux-Ruff, C., 2012. δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J. Pharmacol. Exp. Ther. 342, 799-807.
101. Okine, B.N., Norris, L.M., Woodhams, S., Burston, J., Patel, A., Alexander, S.P., Barrett, D.A., Kendall, D.A., Bennett, A.J., Chapman, V., 2012. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behavior: evidence for plastic changes in the endocannabinoid system. Br. J. Pharmacol. 167, 627-640.
102. Ossipov, M.H., Lai, J., Vanderah, T.W., Porreca, F., 2003. Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci. 73, 783-800.
103. Pacheco, D.F., Klein, A., Perez, A.C., Pacheco, C.M.F., Francischi, J.N., Duarte, I.D., The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br. J. Pharmacol. 154, 1143-1149.
104. Pacheco, D.F., Klein, A., Perez, A.C., Pacheco, C.M.F., Francischi, J.N., Reis, G.M.L., Duarte, I.D.G., 2009. Central antinociception induced by μ-opioid receptor agonist morphine, but not δ- or κ- is mediated by cannabinoid CB1 receptor. Br. J. Pharmacol. 158, 225-231.
105. Páldy, E., Bereczki, E., Sántha, M., Wenger, T., Borsodi, A., Zimmer, A., Benyhe, S., CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem. Int. 53, 309-316.
106. Parikh, D., Hamid, A., Friedman, T.C., Nguyen, K., Tseng, A., Marquez, P., Lutfy, K., Stress-induced analgesia and endogenous opioid peptides: the importance of stress duration. Eur. J. Pharmacol. 650, 563-567.
107. Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P., Di Marzo, V., Elphick, M.R., Greasley, P.J., Hansen, H.S., Kunos, G., Mackie, K., Mechoulam, R., Ross, R.A., International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol. Rev. 62, 588-631.
108. Petraschka, M., Li, S., Gilbert, T.L., Westenbroek, R.E., Bruchas, M.R., Schreiber, S., Lowe, J., Low, M.J., Pintar, J.E., Chavkin, C., 2007. The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation. Neuroscience 146, 1795-1807.
109. Pol, O., Murtra, P., Caracuel, L., Valverde, O., Puig, M.M., Maldonado, R., 2006. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. Neuropharmacology 50, 123-132.
110. Qiu, C., Sora, I., Ren, K., Uhl, G., Dubner, R., 2000. Enhanced delta-opioid receptormediated antinociception in mu-opioid receptor-deficient mice. Eur. J. Pharmacol. 387, 163-169. (Erratum in Eur. J. Pharmacol. 397, 227).
111. Qiu, J., Bosch, M.A., Tobias, S.C., Grandy, D.K., Scanlan, T.S, Ronnekleiv, O.K, Kelly, M. J., 2003. Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J. Neurosci. 23, 9529-9540.
112. Racz, I., Nadal, X., Alferink, J., Baños, J.E., Rehnelt, J., Martin, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Manzanares, J., Zimmer, A., Maldonado, R., 2008a. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci. 28, 12125-12135.
113. Racz, I., Nadal, X., Alferink, J., Baños, J.E., Rehnelt, J., Martin, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Bellora, N., Manzanares, J., Zimmer, A., Maldonado, R., 2008b. Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J. Neurosci. 28, 12136-12145.
114. Raghavendra, V., Tanga, F., DeLeo, J.A., 2003. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306, 624-630.
115. Ragnauth, A., Schuller, A., Morgan, M., Chan, J., Ogawa, S., Pintar, J., Bodnar, R.J., Pfaff, D.W., 2001. Female preproenkephalin-knockout mice display altered emotional responses. Proc. Natl. Acad. Sci. USA 98, 1958-1963.
116. Richardson, J.D., Aanonsen, L., Hargreaves, K., 1998. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18, 451-457.
117. Rittner, H.L., Brack, A., Stein, C., 2008. Pain and the immune system. Br. J. Anaesth. 101, 40-44.
118. Roques, B.P., Fournié-Zaluski, M.C., Wurm, M., 2012. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat. Rev. Drug Discov. 11, 292-310, http://dx.doi.org/10.1038/nrd3673.
119. Rothman, R.B., Brady, L.S., Xu, H., Long, J.B., 1993. Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro- Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain. Peptides 14, 1271-1277.
120. Rubinstein, M., Mogil, J.S., Japón, M., Chan, E.C., Allen, R.G., Low, M.J., 1996. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 93, 3995-4000.
121. Russo, R., Loverme, J., La Rana, G., Compton, T., Parrot, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., Piomelli, D., 2007. The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 322, 236-242.
122. Sagar, D.R., Gaw, A.G., Okine, B.N., Woodhams, S.G., Wong, A., Kendall, D.A., Chapman, V., 2009. Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol. Pain. 8, 5-59.
123. (-/-) mice in models of acute and persistent pain. Neuropharmacology 57, 235-241.
124. Saria, A., Hauser, K.F., Traurig, H.H., Turbek, C.S., Hersh, L., Gerard, C., 1997. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice. Neurosci. Lett. 234, 27-30.
125. Schepers, R.J., Mahoney, J.L., Gehrke, B.J., Shippenberg, T.S., 2008. Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation. Pain 138, 423-439.
126. Schlosburg, J.E., Blankman, J.L., Long, J.Z., Nomura, D.K., Pan, B., Kinsey, S.G., Nguyen, P.T., Ramesh, D., Booker, L., Burston, J.J., Thomas, E.A., Selley, D.E., Sim-Selley, L. J., Liu, Q.S., Lichtman, A.H., Cravatt, B.F., 2010. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113-1119.
127. Schuller, A.G., King, M.A., Zhang, J., Bolan, E., Pan, Y.X., Morgan, D.J., Chang, A., Czick, M.E., Unterwald, E.M., Pasternak, G.W., Pintar, J.E., 1999. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. 2, 151-156.
128. Sharifi, N., Diehl, N., Yaswen, L., Brennan, M.B., Hochgeschwender, U., 2001. Generation of dynorphin knockout mice. Brain Res. Mol. Brain Res. 86, 70-75.
129. Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A., Le Meur, M., Roques, B.P., Maldonado, R., Kieffer, B.L., 1998. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17, 886-897.
130. Simonin, F., Slowe, S., Becker, J.A., Matthes, H.W., Filliol, D., Chluba, J., Kitchen, I., Kieffer, B.L., 2001. Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur. J. Pharmacol. 414, 189-195.
131. Sora, I., Takahashi, N., Funada, M., Ujike, H., Revay, R.S., Donovan, D.M., Miner, L.L., Uhl, G.R., 1997. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA 94, 1544-1549.
132. Sora, I., Li, X.F., Funada, M., Kinsey, S., Uhl, G.R., 1999. Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488. Eur J Pharmacol. 366, R3-5.
133. Staton, P.C., Hatcher, J.P., Walker, D.J., Morrison, A.D., Shapland, E.M., Hughes, J.P., Chong, E., Mander, P.K., Green, P.J., Billinton, A., Fulleylove, M., Lancaster, H.C., Smith, J.C., Bailey, L.T., Wise, A., Brown, A.J., Richardson, J.C., Chessell, I.P., 2008. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with in.ammatory and neuropathic pain. Pain 139, 225-236.
134. Stein, C., 1993. Peripheral mechanisms of opioid analgesia. Anesth. Analg. 76, 182-191.
135. Taylor, B.K., 2009. Spinal inhibitory neurotransmission in neuropathic pain. Curr. Pain Headache Rep. 13, 208-214.
136. Tian, M., Broxmeyer, H.E., Fan, Y., Lai, Z., Zhang, S., Aronica, S., Cooper, S., Bigsby, R. M., Steinmetz, R., Engle, S.J., Mestek, A., Pollock, J.D., Lehman, M.N., Jansen, H.T., Ying, M., Stambrook, P.J., Tischfield, J.A., Yu, L., 1997. Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J. Exp. Med. 185, 1517-1522.
137. Tsuda, M., Inoue, K., Salter, M.W., 2005. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci. 28, 101-107.
138. Valenzano, K.J., Tafesse, L., Lee, G., Harrison, J.E., Boulet, J.M., Gottshall, S.L., Mark, L., Pearson,M.S., Miller,W., Shan, S., Rabadi, L., Rotshteyn, Y., Chaffer, S.M., Turchin, P.I., Elsemore, D.A., Toth, M., Koetzner, L., Whiteside, G.T., 2005. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48, 658-672.
139. Valverde, O., Ledent, C., Beslot, F., Parmentier, M., Roques, B.P., 2000a. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur. J. Neurosci. 12, 533-539.
140. Valverde, O., Maldonado, R., Valjent, E., Zimmer, A.M., Zimmer, A., 2000b. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knockout mice. J. Neurosci. 15, 9284-9289.
141. Van, S., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, V., Pittman, Q. J., Patel, K.D., Sharkey, K.A., 2005. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
142. Vaughan, C.W., Connor, M., Bagley, E.E., Christie, M.J., 2000. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 57, 288-295.
143. Wang, Z., Gardell, L.R., Ossipov, M.H., Vanderah, T.W., Brennan, M.B., Hochgesch-wender, U., Hruby, V.J., Malan Jr., T.P., Lai, J., Porreca, F., 2001. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci. 21, 779-786.
144. Watkins, L.R., Milligan, E.D., Maier, S.F., 2001. Glial activation: a driving force for pathological pain. Trends Neurosci. 24, 450-455.
145. Watkins, L.R., Milligan, E.D., Maier, S.F., 2003. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv. Exp. Med. Biol. 521, 1-21.
146. Whiteside, G.T., Gottshall, S.L., Boulet, J.M., Chaffer, S.M., Harrison, J.E., Pearson, M. S., Turchin, P.I., Mark, L., Garrison, A.E., Valenzano, K.J., 2005. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur. J. Pharmacol. 528, 65-72.
147. Wilson, R.I., Nicoll, R.A., 2002. Endocannabinoid signaling in the brain. Science 296, 678-682.
148. Wise, L.E., Shelton, C.C., Cravatt, B.F., Martin, B.R., Lichtman, A.H., 2007. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur. J. Pharmacol. 557, 44-48.
149. Xu, M., Petraschka, M., McLaughlin, J.P., Westenbroek, R.E., Caron, M.G., Lefkowitz, R.J., Czyzyk, T.A., Pintar, J.E., Terman, G.W., Chavkin, C., 2004. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J. Neurosci. 24, 4576-4584.
150. Yamamoto, W., Mikami, T., Iwamura, H., 2008. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur. J. Pharmacol. 583, 56-61.
151. Yu, X.H., Cao, C.Q., Martino, G., Puma, C., Morinville, A., St-Onge, S., Lessard, E., Perkins, M.N., Laird, J.M., 2010. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 151, 337-344.
152. Zadina, J.E., Hackler, L., Ge, L.J., Kastin, A.J., 1997. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386, 499-502.
153. Zhang, Y., Li, H., Li, Y., Sun, X., Zhu, M., Hanley, G., Lesage, G., Yin, D., 2011. Essential role of toll-like receptor 2 in morphine-induced microglia activation in mice. Neurosci. Lett. 489, 43-47.
154. Zhu, Y., King, M.A., Schuller, A.G., Nitsche, J.F., Reidl, M., Elde, R.P., Unterwald, E., Pasternak, G.W., Pintar, J.E., 1999. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24, 243-252.
155. Zimmer, A., Valjent, E., Konig, M., Zimmer, A.M., Robledo, P., Hahn, H., Valverde, O., Maldonado, R., 2001. Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J. Neurosci. 21, 9499-9505.
156. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M., Bonner, T.I., 1999. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 5780-5785.